Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS)

Andreas, S., Chouaid, C., Danson, S. orcid.org/0000-0002-3593-2890 et al. (15 more authors) (2018) Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). Lung Cancer.

Abstract

Metadata

Authors/Creators:
  • Andreas, S.
  • Chouaid, C.
  • Danson, S. https://orcid.org/0000-0002-3593-2890
  • Siakpere, O.
  • Benjamin, L.
  • Ehness, R.
  • Dramard-Goasdoue, M.-H.
  • Barth, J.
  • Hoffmann, H.
  • Potter, V.
  • Barlesi, F.
  • Chirila, C.
  • Hollis, K.
  • Sweeney, C.
  • Price, M.
  • Wolowacz, S.
  • Kaye, J.A.
  • Kontoudis, I.
Copyright, Publisher and Additional Information: © 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
Keywords: Adjuvant therapy; Cost of adverse event; Direct cost; Economic burden; Indirect cost; Non-small cell lung cancer (NSCLC)
Dates:
  • Published (online): 9 June 2018
  • Accepted: 8 June 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 16 Aug 2018 09:55
Last Modified: 16 Aug 2018 09:55
Published Version: https://doi.org/10.1016/j.lungcan.2018.06.007
Status: Published online
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.lungcan.2018.06.007
Related URLs:

Share / Export

Statistics